- Home
- NWL vs AUPH Comparison
NWL vs AUPH Comparison
Compare NWL & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NWL | AUPH |
|---|---|---|
| Founded | 1903 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | NWL | AUPH |
|---|---|---|
| Price | $3.93 | $15.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | $5.91 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 6.0M | 1.1M |
| Earning Date | 02-06-2026 | 11-04-2025 |
| Dividend Yield | ★ 7.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | ★ $7,256,000,000.00 | $265,808,000.00 |
| Revenue This Year | N/A | $21.76 |
| Revenue Next Year | $0.15 | $16.45 |
| P/E Ratio | ★ N/A | $27.81 |
| Revenue Growth | N/A | ★ 20.62 |
| 52 Week Low | $3.07 | $6.55 |
| 52 Week High | $10.85 | $16.54 |
Technical Indicators
Market Signals| Indicator | NWL | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 59.04 | 46.41 |
| Support Level | $3.68 | $14.82 |
| Resistance Level | $3.86 | $15.98 |
| Average True Range (ATR) | 0.12 | 0.40 |
| MACD | 0.02 | -0.15 |
| Stochastic Oscillator | 86.08 | 34.59 |
Price Performance
Historical ComparisonAbout NWL Newell Brands Inc.
Newell Brands Inc is an American consumer goods company with a portfolio of brands, including Rubbermaid, Sharpie, Graco, Coleman, Rubbermaid Commercial Products, Yankee Candle, Paper Mate, FoodSaver, Dymo, EXPO, Elmer's, Oster, NUK, Spontex and Campingaz. The group is focused on delighting consumers by lighting up everyday moments. Its segments are Home and Commercial Solutions, Learning and Development, and Outdoor and Recreation. The group geographic areas are the United States, Canada, Europe, the Middle East and Africa, Asia Pacific, and Latin America.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.